Table 1 Cohort demographics
|  | Reference range | Controls (n = 9) | ApoBR3500Q | P-value | |
|---|---|---|---|---|---|
Heterozygotes (n = 13) | Homozygotes (n = 3) | ||||
Age (years) | NA | 16 (7–26) | 14 (3–28) | 9 (4–22) | 0.707 |
Males [n (%)] | NA | 5 (56) | 8 (62) | 2 (67) | 1.000 |
Body mass index (kg/m2) | 18.5—24.9 | 21.5 (15.8–25.6) | 17.9 (14.7–24.5) | 13.9 (13.8–15.6) | 0.124 |
Systolic blood pressure (mmHg) | NA | 110 (96–130) | 100 (90–140) | 90 (90–120) | 0.416 |
Hemoglobin A1c (%) |  ≤ 5.6 | 5.4 (5.1–5.8) | 5.2 (4.7–5.7) | 5.3 (5.3–5.4) | 0.220 |
Free fatty acids (mmol/L) |  < 0.60 | 0.4 (0.3–0.7) | 0.5 (0.2–1.4) | 0.7 (0.5–0.7) | 0.383 |
Homocysteine (μmol/L) |  < 11 | 6 (5–12) | 6 (4–10) | 6 (5–6) | 0.853 |
Alanine aminotransferase (U/L) |  < 34 | 16 (11–87) | 18 (8–77) | 16 (14–20) | 0.831 |
Estimated GFR (mL/min/1.73 m2) |  > 89 | 127 (93–150) | 130 (104–150) | 91 (79–150) | 0.831 |
Thyroid stimulating hormone (μIU/mL) | 0.27–4.20 | 2.5 (1.6–3.2) | 2.5 (0.7–5.6) | 3.0 (1.3–3.2) | 0.695 |
High-sensitivity CRP (mg/L) |  < 1.0 | 0.7 (0.3–2.4) | 0.3 (0.3–1.9) | 1.1 (0.3–11.9) | 0.159 |
Fibrinogen (mg/dL) | 126–437 | 352 (274–513) | 333 (239–476) | 387 (234–601) | 0.647 |
Lipoprotein-associated phospholipase A2 (ng/mL) |  < 200 | 151 (130–250) | 184 (144–239) | 226 (161–231) | 0.299 |
Myeloperoxidase (pmol/L) |  ≤ 320 | 318 (240–414) | 291(207–672) | 292 (205–381) | 0.209 |
Total cholesterol (mg/dL) | NA | 168 (126–255) | 225 (149–297) | 396 (333–399) | 0.021 |
LDL-C (mg/dL) | NA | 95 (59–154) | 165 (101–219) | 304 (288–341) | 0.001 |
HDL-C (mg/dL) | NA | 71 (45–95) | 58 (40–100) | 66 (54–87) | 0.403 |
Triglycerides (mg/dL) | NA | 32 (28–96) | 38 (28–98) | 53 (43–56) | 0.566 |